Worldquant Millennium Advisors LLC acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 121,275 shares of the biopharmaceutical company's stock, valued at approximately $127,489,000. Regeneron Pharmaceuticals makes up about 0.9% of Worldquant Millennium Advisors LLC's investment portfolio, making the stock its 22nd largest holding. Worldquant Millennium Advisors LLC owned about 0.11% of Regeneron Pharmaceuticals at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. SteelPeak Wealth LLC boosted its holdings in Regeneron Pharmaceuticals by 173.0% during the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company's stock worth $1,148,000 after buying an additional 692 shares in the last quarter. Mizuho Securities USA LLC boosted its stake in shares of Regeneron Pharmaceuticals by 625.5% during the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company's stock worth $62,382,000 after acquiring an additional 51,162 shares in the last quarter. Tri Locum Partners LP grew its position in shares of Regeneron Pharmaceuticals by 104.5% during the 2nd quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company's stock valued at $18,410,000 after acquiring an additional 8,949 shares during the period. Simplify Asset Management Inc. increased its stake in shares of Regeneron Pharmaceuticals by 50.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company's stock valued at $10,082,000 after purchasing an additional 3,231 shares in the last quarter. Finally, Catalytic Wealth RIA LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $1,334,000. Institutional investors and hedge funds own 83.31% of the company's stock.
Analyst Upgrades and Downgrades
Several analysts have commented on the company. Citigroup began coverage on Regeneron Pharmaceuticals in a report on Thursday, November 14th. They issued a "neutral" rating and a $895.00 price objective on the stock. Morgan Stanley dropped their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a "buy" rating for the company in a research report on Friday, November 1st. Evercore ISI dropped their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating on the stock in a research report on Thursday, October 24th. Finally, Barclays reduced their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating for the company in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $1,107.29.
View Our Latest Research Report on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Trading Up 1.3 %
Regeneron Pharmaceuticals stock traded up $10.10 during midday trading on Friday, hitting $778.00. 813,637 shares of the stock were exchanged, compared to its average volume of 546,782. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $85.49 billion, a price-to-earnings ratio of 19.25, a PEG ratio of 2.89 and a beta of 0.08. The stock's 50-day simple moving average is $882.14 and its 200 day simple moving average is $1,013.01. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $735.95 and a fifty-two week high of $1,211.20.
Regeneron Pharmaceuticals Company Profile
(
Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Featured Articles
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
